Preimplantation Genetic Testing Market Study Highlights How Industry Demand Is Evolving

The preimplantation genetic testing sector is poised for significant expansion as advancements in reproductive technologies continue to evolve. Rising demand for personalized treatment options and innovative genetic screening techniques are key factors shaping the market's promising outlook. Let's explore the market's size projections, influential players, emerging trends, and the main segments driving growth through 2030.

Preimplantation Genetic Testing Market Size and Growth Outlook
The preimplantation genetic testing market is set to experience rapid growth, reaching a valuation of $1.57 billion by 2030. This corresponds to a robust compound annual growth rate (CAGR) of 11.1%. The expansion over this period is driven by multiple factors including a surge in personalized reproductive medicine, broader adoption of cutting-edge genomic technologies, the growing availability of fertility preservation services, increased investments in reproductive health infrastructure, and wider regulatory acceptance of genetic screening procedures. Key trends anticipated during this timeframe involve greater use of embryo screening, integration of next-generation sequencing (NGS) in IVF treatments, expansion of genetic testing for fertility purposes, rising demand to improve implantation success rates, and a stronger focus on minimizing genetic disorders.

The preimplantation genetic testing market size has grown rapidly in recent years. It will grow from $0.92 billion in 2025 to $1.03 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increasing utilization of assisted reproductive technologies, advancements in embryo biopsy techniques, growing awareness of genetic disease prevention, expansion of fertility clinics, improving IVF success outcomes.

Download a free sample of the preimplantation genetic testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20596&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Propelling Growth in the Preimplantation Genetic Testing Market
One of the primary forces fueling market growth is the increasing emphasis on personalized reproductive healthcare. Patients and clinicians alike are seeking more precise and tailored approaches to fertility treatments, which preimplantation genetic testing can effectively provide by helping to select the healthiest embryos.
In addition, technological advances such as next-generation sequencing and other sophisticated genomic methods are enabling more accurate and comprehensive embryo evaluations. This progress not only enhances success rates in assisted reproduction but also broadens the scope of detectable genetic conditions, encouraging wider market adoption.

Leading Players Making an Impact in the Preimplantation Genetic Testing Market
The market features a range of influential companies that play critical roles in advancing preimplantation genetic testing technologies. These include Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Revvity Health Science Inc., CooperSurgical Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Invitae Corporation, Takara Bio Inc., MedGenome Labs Ltd., Genea Limited, Ovation Fertility, Juno Genetics Ltd, Invicta Genetics, Progenesis, Bioarray SL, PacGenomics, Reproductive Genetic Innovations LLC, and SEQUENCE46 LLC.

View the full preimplantation genetic testing market report:
https://www.thebusinessresearchcompany.com/report/preimplantation-genetic-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Collaborations Highlighting Innovation in the Market
In April 2024, GenEmbryomics, an embryo genetic testing service provider from Australia, collaborated with Progenesis Inc., a US-based laboratory specializing in IVF and preimplantation genetic testing services. This partnership aims to offer a full spectrum of preimplantation genetic testing options including PGT-A, PGT-M, PGT-SR, and PGT-WGS. Their joint efforts seek to expand access to advanced embryo genetic screening for IVF clinics and patients, improving embryo selection accuracy and empowering informed reproductive choices. This collaboration reflects the market's growing focus on comprehensive genome-wide screening and state-of-the-art reproductive genomics solutions.

Emerging Technological Trends in the Preimplantation Genetic Testing Market
A significant trend emerging within the market is the development of advanced next-generation sequencing (NGS) tools by leading companies. These innovations improve the precision, efficiency, and speed of genetic screening, enabling more thorough analyses and better-informed decisions for prospective parents.
For example, in July 2023, Thermo Fisher Scientific introduced the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, next-generation sequencing products designed to enhance research in IVF and ICSI. These kits streamline the entire workflow from sample processing to aneuploidy detection using the Ion Torrent Genexus integrated sequencer, marking a breakthrough in embryo screening technology and boosting success rates in assisted reproduction.

Key Market Segments Influencing Growth in Preimplantation Genetic Testing
This report breaks down the preimplantation genetic testing market into several important categories:
1) By Procedure: Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD)
2) By Product: Reagents and Consumables, Instruments, and Software
3) By Technology: Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In Situ Hybridization (FISH), and other methods
4) By Application: Chromosomal Abnormalities, Aneuploidy Screening, X-Linked Diseases, Embryo Testing, Human Leukocyte Antigen (HLA) Typing, among others
5) By End User: Hospitals, Fertility Centers, Diagnostic Centers, Research Centers, and Academic Laboratories

Further divisions include subtypes under PGS such as Array Comparative Genomic Hybridization (aCGH), Next-Generation Sequencing (NGS), and Fluorescence In Situ Hybridization (FISH). For PGD, the subsegments consist of Monogenic Disorders Testing, Chromosomal Abnormalities Testing, and HLA Typing for Stem Cell Transplantation.

This detailed segmentation provides a comprehensive view of the various components driving the evolution and expansion of the preimplantation genetic testing market through 2030.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.